2022_Oct_PODD_Boston_ Skyscraper2

Stabilitech

Stabilitech Biopharma is applying its patented THERM-SB platform, for the thermo-stabilisation of viruses, vaccines, proteins and biopharmaceuticals, in the development of various technologies including  the OraPro™ oral delivery system for biopharmaceuticals and vaccines.


Visit Website

Company Address:
Sabilitech Biopharma Ltd
Unit 6 Sovereign Business Park
Albert Drive
Burgess Hill
RH15 9TY
United Kingdom

Phone / Contact

T: +44 1444 241911

Connect

Stabilitech Biopharma is applying its patented THERM-SB platform, for the thermo-stabilisation of viruses, vaccines, proteins and biopharmaceuticals, in the development of various technologies including  the OraPro™ oral delivery system for biopharmaceuticals and vaccines, which:

  • enables oral administration of non-replicating vector
  • enables repeat administration with the same vector carrying the same or new payload
  • enables transient biopharmaceutical production induced within the human/patient gut
  • is suitable for vaccines, therapeutic proteins, enzyme replacement, etc
  • forms a thermally stable oral capsule
  • allows for the re-use of a vector for new developments / enables re-use of large parts of the regulatory dossier

Therm-SB is a formulation of simple sugars and non-toxic small molecules in discrete concentrations and ratios that are mixed with the vaccine during the fill-finish process.

The company has partnerships with several pharma companies including GSK and it seeks additional partnerships for the development of products based on its THERM-SB platform and the OraPro™ technology.

Articles by Stabilitech

Top